Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.

NCT Number	NCT07126236
Lead Sponsor	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea Collaborators: AbbVie, Incyte Corporation, Evidenze CRO
Conditions	Large B Cell Lymphoma
Enrollment	80 participants
Start Date	2025-08-04
Primary Completion	2031-12 (estimated)
Study Completion	2031-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-17